Citigroup’s Pacific Biosciences PACB Stock Holding History

Citigroup’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-100,000	Closed	-$581K	–	5909
2022 Q3	$581K	Buy	+100,000	New	+$574K	﹤0.01%	3132
2020 Q1	–	Sell	-1,100	Closed	-$6K	–	7732
2019 Q4	$6K	Buy	1,100 +600	+120%	+$3.05K	﹤0.01%	7355
2019 Q3	$3K	Hold	500	–	–	﹤0.01%	7475
2019 Q2	$3K	Sell	500 -6,500	-93%	-$45.6K	﹤0.01%	7571
2019 Q1	$51K	Sell	7,000 -2,600	-27%	-$18.8K	﹤0.01%	6329
2018 Q4	$71K	Buy	9,600 +7,100	+284%	+$45K	﹤0.01%	5946
2018 Q3	$14K	Buy	+2,500	New	+$10.7K	﹤0.01%	7242
2017 Q4	–	Sell	-10,300	Closed	-$54K	–	7625
2017 Q3	$54K	Buy	10,300 +3,500	+51%	+$15K	﹤0.01%	5960
2017 Q2	$24K	Buy	6,800 +4,300	+172%	+$17.3K	﹤0.01%	6194
2017 Q1	$13K	Buy	+2,500	New	+$12.2K	﹤0.01%	6467
2016 Q3	–	Sell	-500	Closed	-$4K	–	7149
2016 Q2	$4K	Buy	+500	New	+$4.57K	﹤0.01%	6825

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citigroup's PACB Position: Q2 2026 in Review

Citigroup increased its Pacific Biosciences (PACB) stake by 321% in Q2 2026, buying an estimated $155K and bringing the position to 139,424 shares worth $234K. The position accounts for ﹤0.01% of the portfolio, ranked #4260.

Citigroup first reported a position in PACB in Q2 2013 and has held it in 53 quarters since. The position peaked at $16.3M in Q1 2019. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Citigroup held 139,424 shares of Pacific Biosciences worth $234K as of Q2 2026.
Citigroup bought 106,325 Pacific Biosciences shares in Q2 2026, an estimated $155K.
Pacific Biosciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4260 holding.
Citigroup first reported a position in Pacific Biosciences in Q2 2013 and has held it in 53 quarters since.
Citigroup's Pacific Biosciences position peaked at $16.3M in Q1 2019.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.